Cell3™ Preserver

Whole Blood Stabilization Tube

Whole blood stabilization tubes for cfDNA (circulating free DNA)

In genetic testing, the quality of blood samples significantly impacts the reliability of results. Cell3™ Preserver is a product developed with advanced blood preservation technology to address this challenge effectively.

The table of contents

Product Features

Enhanced Blood Stability

Cell3™ Preserver stabilizes whole blood at room temperature for up to 15 days, ensuring sample quality is maintained even during long-distance transportation or unexpected delays.

Versatile Applications

Validated across various testing applications, including non-invasive prenatal testing (NIPT) and liquid biopsy, the product supports high data quality across multiple platforms, meeting diverse needs.

Plastic Evacuated Tube with Standard Tube Format

Designed for safe and easy handling, the tube avoids the breakage risks associated with glass, making it compatible with standard collection equipment and disposable tools.

Data Validated on Multiple Platforms

Performance has been validated across various methodologies, including qPCR, DNA fragment analysis, and NGS (whole-genome and targeted sequencing). Results show performance equal to or better than other products in the market.

NIPT

Blood samples from five patients were preserved in both Cell3™ Preserver and a competitor tube from Company S. Plasma separation was performed five days post-collection for Company S’s tube, and on both days 5 and 11 for Cell3™ Preserver. cfDNA was extracted for NIPT analysis to detect fetal chromosomal abnormalities (aneuploidies). Accurate results were obtained for all samples (e.g., two male, two female normal karyotypes, and one case of monosomy X). Additionally, the fetal DNA fraction showed consistent levels across all time points (Figure 1).

Liquid Biopsy

Blood samples from metastatic breast cancer patients post-chemotherapy were preserved using both Cell3™ Preserver and a competitor tube from Company S. ctDNA (cfDNA) extracted from these samples was analyzed alongside gDNA extracted from white blood cells and gDNA from tumor tissue preserved in FFPE (formalin-fixed, paraffin-embedded). Targeted sequencing was conducted on cancer-associated genes using Illumina sequencing technology. Bioinformatics analysis identified variants (mutations) in detail, pinpointing key variants linked to therapeutic relevance. Variant frequencies from samples preserved in Cell3™ Preserver and Company S’s tube were calculated and compared. Two pathogenic variants were confirmed in both gDNA (FFPE) and ctDNA, but were absent in gDNA derived from white blood cells (germline origin) (Figure 2).